Literature DB >> 9707314

Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.

S López-Hernández1, T Alarcón, M López-Brea.   

Abstract

Four patients colonized/infected with carbapenem-resistant strains of Acinetobacter baumannii are described. The first patient had a decubitus ulcer infection and had been on intravenous imipenem for 50 days. Two other patients, from whom Acinetobacter baumannii was isolated from urine, were hospitalized in the same ward as the first patient. The fourth patient had been mechanically ventilated in the intensive care unit for 4 month and had nosocomial pneumonia. He had been on intravenous meropenem for 1 month. Minimum inhibitory concentrations (MICs) of imipenem (128 mg/l) and meropenem (> 128 mg/l) were the same for the isolates from the first three patients, and all of these isolates had the same repetitive extragenic palindromic polymerase chain reaction (rep-PCR) pattern. The MICs of carbapenems were lower for patient 4's isolate, which also had a different rep-PCR pattern. Beta-lactamases that hydrolyzed imipenem were detected in all four isolates; isoelectric points were 8.6-7.7 in the first three isolates and 6.8-7 in the fourth isolate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707314     DOI: 10.1007/bf01699988

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Investigation of a multiyear multiple critical care unit outbreak due to relatively drug-sensitive Acinetobacter baumannii: risk factors and attributable mortality.

Authors:  R Kaul; J A Burt; L Cork; H Dedier; M Garcia; C Kennedy; J Brunton; M Krajden; J Conly
Journal:  J Infect Dis       Date:  1996-12       Impact factor: 5.226

2.  Distribution of beta-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus.

Authors:  M L Joly-Guillo; E Vallée; E Bergogne-Bérézin; A Philippon
Journal:  J Antimicrob Chemother       Date:  1988-11       Impact factor: 5.790

3.  Nosocomial outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-control and molecular epidemiologic investigations.

Authors:  E G Scerpella; A R Wanger; L Armitige; P Anderlini; C D Ericsson
Journal:  Infect Control Hosp Epidemiol       Date:  1995-02       Impact factor: 3.254

4.  Emergence of resistant isolates of Acinetobacter calcoaceticus- A. baumannii complex in a Spanish hospital over a five-year period.

Authors:  M I García-Arata; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

5.  ARI 1: beta-lactamase-mediated imipenem resistance in Acinetobacter baumannii.

Authors:  R Paton; R S Miles; J Hood; S G Amyes; R S Miles; S G Amyes
Journal:  Int J Antimicrob Agents       Date:  1993-02       Impact factor: 5.283

6.  Endemic Acinetobacter anitratus in a surgical intensive care unit: mechanical ventilators as reservoir.

Authors:  C M Vandenbroucke-Grauls; A J Kerver; J H Rommes; R Jansen; C den Dekker; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

7.  Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var anitratus: epidemiologic characteristics and clinical significance.

Authors:  J E Peacock; L Sorrell; F D Sottile; L E Price; W A Rutala
Journal:  Infect Control Hosp Epidemiol       Date:  1988-07       Impact factor: 3.254

8.  Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.

Authors:  C Urban; E Go; N Mariano; B J Berger; I Avraham; D Rubin; J J Rahal
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226

9.  A comparative study of different PCR-based DNA fingerprinting techniques for typing of the Acinetobacter calcoaceticus-A. baumannii complex.

Authors:  J Vila; M A Marcos; M T Jimenez de Anta
Journal:  J Med Microbiol       Date:  1996-06       Impact factor: 2.472

10.  The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents.

Authors:  E Bergogne-Bérézin
Journal:  J Hosp Infect       Date:  1995-06       Impact factor: 3.926

View more
  7 in total

1.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  The increasing role of Acinetobacter species as nosocomial pathogens.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Curr Infect Dis Rep       Date:  2007-10       Impact factor: 3.725

3.  The molecular epidemiological study of colistin-only-sensitive strains in multi-drug resistant Acinetobacter baumannii.

Authors:  Li Yang; Lizhong Han; Jingyong Sun; Yunsong Yu; Yuxing Ni
Journal:  Front Med China       Date:  2007-10

4.  In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.

Authors:  Paul G Higgins; Hilmar Wisplinghoff; Danuta Stefanik; Harald Seifert
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 5.  Antibiotic-Resistant Acinetobacter baumannii Increasing Success Remains a Challenge as a Nosocomial Pathogen.

Authors:  Ana Maria Gonzalez-Villoria; Veronica Valverde-Garduno
Journal:  J Pathog       Date:  2016-02-04

6.  Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Cheng-Yi Chen; Wen-Hwei Chen; Chong-Jen Yu; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

Review 7.  Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.

Authors:  Shio-Shin Jean; Yin-Chun Chang; Wei-Cheng Lin; Wen-Sen Lee; Po-Ren Hsueh; Chin-Wan Hsu
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.